<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04492267</url>
  </required_header>
  <id_info>
    <org_study_id>7930</org_study_id>
    <nct_id>NCT04492267</nct_id>
  </id_info>
  <brief_title>Inflammatory Bowel Disease (IBD) and Covid-19 Infection</brief_title>
  <acronym>MICI-Covid-19</acronym>
  <official_title>SARS-CoV-2 Infection in Patients From Two Tertiary Inflammatory Bowel Disease (IBD) Centres: Frequency of Suspected and Confirmed Infections, Severity and Outcome Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a
      tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically,
      these treatments may increase patients' risk of infection, in particular viral infection.
      Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and
      mortality, may have a negative impact on IBD patients' clinical course. Identifying an
      increased risk in this particular patients' population as well as the risk/protective factors
      is of outstanding importance, in order to adapt their treatment and surveillance. As a
      consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by
      biological testing or suspected due to record of potential clinical symptoms of COVID-19
      infection) in this patients' cohort (principal objective), (ii) to identify risk or
      protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of
      patients in case of suspected or confirmed COVID-19. The results of this study may be
      important to adjust our surveillance and therapeutic strategy in these patients, in
      particular if high virus circulation will occur in the future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">January 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective analysis of severity and specific needs in case of SARS-CoV-2 infection in IBD patients</measure>
    <time_frame>Files analysed retrospectily from March 1st, 2020 to July 31, 2020 will be examined</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        IBD patient (Crohn's disease, ulcerative colitis, indeterminate colitis) over the age of 18
        years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over the age of 18 years

          -  IBD patients (Crohn's disease, ulcerative colitis, indeterminate colitis)

          -  Patient agreeing to participate in the study

        Exclusion Criteria:

          -  Patient unable to understand the study protocol or to answer simple anamnestic
             questions due to language barrier

          -  Patient under guardianship or trusteeship

          -  Patient under safeguard of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Marie REIMUND, MD, PhD</last_name>
    <phone>33 3 88 12 74 41</phone>
    <email>jean-marie.reimund@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service Hépato-Gastroentérologie et Assistance Nutritive Hôpitaux Univesitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie REIMUND, MD, PhD</last_name>
      <phone>33 3 88 12 74 41</phone>
      <email>jean-marie.reimund@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie REIMUND, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bénédicte CARON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves ARONDEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>IBD</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Immunosuppressant therapy</keyword>
  <keyword>Biologicals</keyword>
  <keyword>Severe respiratory disease</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

